miDiagnostics is developing a portfolio of molecular diagnostic tests, where decentralization (near patient), ease of use, speed and accuracy are important factors to aid physicians in their diagnosis, hence serving the patients better.
Diagnostic testing still relies on sending samples to centralized laboratories, often leading to a delay in receiving results and incorrect or inefficient patient management.
Current alternatives either focus on speed, at the expense of accuracy, or focus on accuracy, but are not easy-to-use and fast enough to deliver a result in a decentralised setting.
miDiagnostics is developing innovative products to fill this gap – combining accuracy, convenience and speed.
Our proprietary reader and test card with silicon chip requires only a small sample, which is drawn through the test card using capillary forces and requires no pump or power.
The reader allows for ultra-fast PCR and the results with lab-quality sensitivity and specificity are visualized on a connected device in a user-friendly user interface
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention.”
“Proud to be leading a top team and together with our numerous partners to make a significant contribution to healthcare in general.”
“As a Non-Executive Director on miDiagnostics’ Board, I have been privileged to witness its continued development. I am very proud to see many years of hard work coming to fruition and providing value, facilitating the return to a normal way of life, with potential to move high quality testing closer to the patient.”
“This technology could aid the management of outbreaks in challenging settings, such as nursing homes and home care environments, allowing healthcare professionals to adjust their management decisions at the point of care. ”